Novavax secures regulatory clearance for its protein-based COVID-19 shot targeting current variants in major markets.
Novavax announced regulatory approvals for its updated COVID-19 vaccine, Nuvaxovid, in the U.S., European Union, and Japan. The shot, developed with Sanofi and Takeda, targets circulating variants and is protein-based, offering an alternative to mRNA vaccines.
The approvals follow earlier versions of Nuvaxovid, which received emergency use authorization in 2022. Analysts had anticipated regulatory clearance by late 2023, aligning with seasonal demand for booster shots. The vaccine remains a key revenue driver for Novavax amid declining global COVID-19 vaccine sales.
Shares of NVAX showed modest gains in premarket trading following the announcement, reflecting investor optimism about the company’s competitive positioning in the vaccine market.